# Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

> **NCT04418024** · PHASE3 · WITHDRAWN · sponsor: **Eidos Therapeutics, a BridgeBio company**

## Conditions studied

- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

## Interventions

- **DRUG:** AG10
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04418024
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-21
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418024, "Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04418024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*